OKI, 150 ml

Pharmacotherapeutic group

Other oral medications.

TAC code: A01AD11.

Pharmacodynamics

It has anti-inflammatory, analgesic effects. By inhibiting cyclooxygenase types I and II, inhibits the synthesis of inflammatory mediators (prostaglandins, thromboxane, etc.). Stabilizes lysosomal membranes and inhibits the release of enzymes that contribute to tissue destruction during inflammation. Inhibits the activity of neutrophils. It has anti-bradykinin activity. The drug does not have antibacterial activity.

Pharmacokinetics

A single dose of 160 mg results in plasma levels of less than 400 ng/mL, insufficient for systemic action.

Indications

Active ingredient

Composition

Active ingredients:

Auxiliary substances:

How to take, the dosage

Two rinses per day, 10 ml of the solution at a time.

10 ml of the solution should be measured with the measuring cup included in the package and diluted in 100 ml (half a cup) of drinking water.

To open the bottle, firmly press the top of the cap and turn it counterclockwise. Firmly screw the cap back on after use.

Inadvertent swallowing of the solution does not have serious consequences, because the single rinse dose contains 160 mg of ketoprofen lysine, which is the same as the oral dose.

Special Instructions

Prolonged use may cause hypersensitivity reactions. In this case, the drug should be discontinued and adequate treatment methods should be chosen.

When using high doses and long-term treatment the absorbable ketoprofen may compete with other drugs that have high affinity for plasma proteins.

The drug contains methyl parahydroxybenzoate, which may cause allergic reactions (including delayed-type allergic reactions).

Influence on driving and operating machinery

There are no data of adverse effects of the drug on the ability to drive vehicles and engage in other potentially dangerous activities requiring concentration and quick psychomotor reactions.

Contraindications

Side effects

Very rare cases of local irritation and angioedema (swelling of the lips, face, throat or tongue) have been reported, especially in patients with hypersensitivity to NSAIDs. Cases of systemic side effects are unknown.

Overdose

There are currently no reported cases of overdose with OCI.

Pregnancy use

Women should not use NSAIDs from the 20th week of pregnancy due to the possible development of oligo and/or renal abnormalities in the newborn (neonatal renal dysfunction). The use of the drug before the 20th week of pregnancy is possible only after consultation with a physician, if the expected benefits to the mother exceed the potential risk to the fetus.

The use of the drug during breastfeeding is not recommended.

Similarities